Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 12/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 11/20 | 0.37 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CFD | P00746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14371780 | 1.00 | ITGA4 (0.37) | ITGA4ITGB1C5AR1PIK3CAMEN1 | |
| SCHEMBL14371632 | 0.93 | ITGA4 (0.38) | ITGA4ITGB1C5AR1PIK3CACFD | |
| SCHEMBL5158598 | 0.93 | ITGA4 (0.38) | ITGA4ITGB1C5AR1PIK3CACFD | |
| SCHEMBL14608792 | 0.90 | ITGA4 (0.36) | ITGA4ITGB1C5AR1PIK3CACFD | |
| SCHEMBL14371778 | 0.89 | ITGB1 (0.49) | ITGA4ITGB1MAPTCFD | |
| SCHEMBL5161433 | 0.89 | ITGB1 (0.49) | ITGA4ITGB1MAPTCFD | |
| SCHEMBL14371771 | 0.87 | ITGA4 (0.40) | ITGA4ITGB1C5AR1PIK3CA | |
| SCHEMBL14371758 | 0.86 | ITGA4 (0.39) | ITGA4ITGB1C5AR1PIK3CA | |
| SCHEMBL5162711 | 0.86 | ITGA4 (0.40) | ITGA4ITGB1C5AR1PIK3CA | |
| SCHEMBL14371921 | 0.83 | ITGA4 (0.39) | ITGA4ITGB1C5AR1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | ITGA4 3/4885ITGB1 9/4885C5AR1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.